Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Celliance was a prominent bioprocessing company specializing in cell culture media supplements and reagents for the biopharmaceutical industry. Formed as a joint venture between Serologicals Corporation and Specialty Laboratories, it was later fully integrated into Serologicals before being acquired by Millipore Corporation in 2006 for approximately $1.4 billion. The company's flagship products include Probumin, a leading brand of high-purity bovine serum albumin (BSA), and EX-CYTE, a growth enhancement media supplement essential for large-scale biomanufacturing. Following the acquisition of Millipore by Merck KGaA, Celliance's technologies were integrated into the MilliporeSigma portfolio, where they continue to support the production of monoclonal antibodies, vaccines, and recombinant proteins.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Celliance.